Search research articles
Contact Us
Filters
Showing results (21-30 of 53) with videos related to
Page
of 6
Sort By:
Lancet (London, England)
|
July 10, 2007
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
José Valdez Madruga, Pedro Cahn, Beatriz Grinsztejn, et al.
AIDS (London, England)
|
April 24, 2018
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
Joseph J Eron, Chloe Orkin, Joel Gallant, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 9, 2013
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results
Andrew Zolopa, Paul E Sax, Edwin DeJesus, et al.
The Lancet. HIV
|
June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Jean-Michel Molina, Douglas Ward, Indira Brar, et al.
Plos One
|
February 14, 2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
Sonia Vibhakar Patel, Dushyantha T Jayaweera, Keri N Althoff, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 22, 2013
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results
David A Wohl, Calvin Cohen, Joel E Gallant, et al.
AIDS Patient Care and Stds
|
March 26, 2014
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis
Georg Behrens, Bart Rijnders, Mark Nelson, et al.
European Journal of Immunology
|
May 10, 2024
HIV rebound in HIV controllers is associated with a specific fecal microbiome profile
Yanhui Cai, Ondrej Podlaha, Steven G Deeks, et al.
Leukemia & Lymphoma
|
January 12, 2019
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia
Masa Lasica, Abbey Willcox, Kate Burbury, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
November 17, 2025
Evaluation of Mycoplasma genitalium positivity and co-infection with Chlamydia trachomatis and/or Neisseria gonorrhoeae at various care sites across the United States
Rebecca Lillis, Rodney Arcenas, Christy M Boraas, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 53) with videos related to
Sort By:
Page
of 6
Lancet (London, England)
|
July 10, 2007
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
José Valdez Madruga, Pedro Cahn, Beatriz Grinsztejn, et al.
AIDS (London, England)
|
April 24, 2018
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
Joseph J Eron, Chloe Orkin, Joel Gallant, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 9, 2013
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results
Andrew Zolopa, Paul E Sax, Edwin DeJesus, et al.
The Lancet. HIV
|
June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Jean-Michel Molina, Douglas Ward, Indira Brar, et al.
Plos One
|
February 14, 2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
Sonia Vibhakar Patel, Dushyantha T Jayaweera, Keri N Althoff, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 22, 2013
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results
David A Wohl, Calvin Cohen, Joel E Gallant, et al.
AIDS Patient Care and Stds
|
March 26, 2014
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis
Georg Behrens, Bart Rijnders, Mark Nelson, et al.
European Journal of Immunology
|
May 10, 2024
HIV rebound in HIV controllers is associated with a specific fecal microbiome profile
Yanhui Cai, Ondrej Podlaha, Steven G Deeks, et al.
Leukemia & Lymphoma
|
January 12, 2019
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia
Masa Lasica, Abbey Willcox, Kate Burbury, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
November 17, 2025
Evaluation of Mycoplasma genitalium positivity and co-infection with Chlamydia trachomatis and/or Neisseria gonorrhoeae at various care sites across the United States
Rebecca Lillis, Rodney Arcenas, Christy M Boraas, et al.
Page
of 6